Welcome to
The Simon Foundation for Continence's
Innovating for Continence
Conference Series

2007 Innovating for Continence - Planning Committee

Alan Cottenden, PhD
Cheryle B. Gartley
Raymond Laborie
Monica Liebert, PhD
Alvin Maslov, BSEE, MSEE, MBA
Christopher K. Payne, MD, FACS
Karl B. Thor, PhD

Alan Cottenden, PhD

Dr Alan Cottenden took a first degree in Materials Science at Cambridge University followed by a CASE studentship PhD in the mechanical properties of machine tool materials at Cambridge and the National Physical Laboratory. He subsequently spent five years at Sussex University , where he developed an interest in incontinence technology. In 1984 he moved to University College London to start a new collaboration with Prof James Malone-Lee (geriatrician) and Dr Mandy Fader (nurse). This persists to the present day as the multi-disciplinary Continence & Skin Technology Group, which addresses the needs of intractably incontinent people and their caregivers.

CSTG work involves numerous collaborations with industry, hospitals, incontinent user groups and universities and current projects range from understanding the fundamental science of absorbency and of incontinence-related skin health, through the development of instrumentation for laboratory and clinical work, product development, and the laboratory and clinical evaluation of existing and prototype products, to work on incontinence-related quality of life and health economic measures.

Dr Cottenden has a particular interest in absorbent products and a major thrust of recent years has been to develop predictive models to facilitate the design of more effective products based on a sound understanding of the interaction between urine and absorbent/porous materials. Complementary work has aimed to establish links between the clinical performance of pads (notably, leakage and wet comfort) and laboratory data. Two large international projects have produced data upon which international standards have been based and a recent study – which established the (non) efficacy of various design features – is being used by the UK NHS Purchasing and Supplies Agency as a basis for placing national contracts with pad suppliers.

Dr Cottenden has published widely in the clinical and technical incontinence literature and recently headed up the international team of writers producing the incontinence products chapter in the book published from the third International Consultation on Incontinence sponsored by the International Continence Society and the World Health Organisation. He holds some 20 patents for incontinence product designs of which the most successful is Kylie Pants, an aesthetically attractive washable absorbent product for lightly incontinent people.

He is on the Advisory Board of the Simon Foundation and a Trustee of the UK Continence Foundation.

Cheryle B. Gartley

Cheryle B. Gartley is the founder and president of The Simon Foundation for Continence, a U.S. based not-for-profit organization dedicated to increasing public and professional awareness about incontinence. Ms. Gartley also co-founded the Canadian Continence Foundation (previously Simon Canada) and served as the first president. The Simon Foundation brings information, educational materials, and help to those who are incontinent, their families, and the health care professionals who provide their care.

Ms. Gartley has published widely in the United States , Japan , Germany , Australia and the United Kingdom , including articles in journals such as the Journal of Urological Nursing, and Social Work Today. Articles about The Simon Foundation and her work have appeared in such national publications as TIME Magazine, Good Housekeeping, and the Ann Landers' column. She is co-author of the first book written on incontinence for the public, Managing Incontinence: A Guide to Living with Loss of Bladder Control, published in three languages.

Ms. Gartley has traveled extensively on behalf of people with incontinence, appearing on hundreds of radio and television talk shows internationally, including People are Talking ( San Francisco ), Kelly and Company ( Detroit ), Good Morning Australia (Sydney) and network news in Japan , Canada , and Germany .

Ms. Gartley co-founded the Continence Promotion Committee of the International Continence Society and is a founding member of the Bladder Health Council of the American Foundation of Urologic Disease (now the AUA Foundation). She was selected as a panelist at the groundbreaking 1988 National Institutes of Health's Consensus Development Conference on Adult Urinary Incontinence. She is a member of the International Standards Organization's Committee on Absorbent Products, the International Continence Society, and the Association of Continence Advisors (UK). She also served with an international team of writers to produce the book published from the first International Consultation on Incontinence and co-chaired the first international conference on Prevention of Incontinence in England in 1997.

Ms. Gartley is a recipient of the AUA's Brantley Scott Award and has been recognized in Outstanding Young Women of America and the World Who's Who of Women. She has a BS in education and journalism and did her graduate work at the University of Chicago 's Graduate School of Business.

Raymond (Ray) Laborie

Born in France .

Landed in Canada October 6th. 1956

Canadian citizen with a U.S. working visa.

Resident of Toronto , Canada and Burlington , Vermont .

1969 Completes commerce (business) studies at University of Toronto and Sir Georges Williams University in Montreal through evening courses (12 years).

Employed in the healthcare industry since 1956.

December 1967: Opens a repair shop in Montreal for Stryker products in response to customers’ demands and with Stryker’s approval.

March 1969: Introduces Karl Storz endoscopes in Canada as a manufacturer’s agent. Karl Storz totally unknown at that point.

October 1971: Sells repair business to give more time to sales activities.

May 1975: Karl Storz K.G. Germany ask Laborie (company) to become their exclusive distributor in Canada . By 1985, Karl Storz products are chosen in 85% of cases in Canada . Also start manufacturing some items for K.STORZ.

1977: Life Tech approach Laborie and within 12 months become the number one supplier of urodynamics equipment in Canada .

1980: Laborie is approached by Pentax , MBB (lasers) and Bruel and Kjaer to introduce their products in Canada .

1982: Because Disa (subsequently Dantec, then Medtronic) had introduced a digital window to read uroflow values, Laborie, in trying a way to apply the concept to all channels, realize that urodynamics can be done with a simple computer: propose this at no cost to all manufacturers of urodynamics equipment: they all refuse.

1984: Laborie introduce the first totally computerized urodynamics system at AUA.

1985: Laborie, with a gynecologist in Quebec , develop a sling system anchored on the symphisis pubis with titanium implants. The product was sold locally but Laborie did not have the marketing clout to approach the US market although both Dr. Ed Mc Guire and Ch. Whitmore saw it and were impressed..

1986: Laborie develops a colonoscope introducer. Develop an inverting concept of their own.

1987: Following Ray’s Mother’s accident and ensuing condition, Laborie decides to dedicate their future to finding better ways to evaluate and treat urinary incontinence issues. Invest considerable time and money into research.

1990: Urodynamics is made easier to do when Laborie introduce Windows as operating system for its urodynamic analyzers.

1992: Laborie develops a device to measure pressure and flow of blood into the corpus cavernosum using photo-pletysmography.

1995: Laborie closes their distribution company in Canada to concentrate on their activities in the incontinence markets throughout the world.

1998: Laborie purchases the stimulation-biofeedback technology from a French manufacturer with the intention of modifying it to meet the demands of the North American market. Since then the device has been completely redone and enjoys great success because of its animation software.

1998: Laborie presents a video at the ICI in Monaco showing 4 new technologies they were working on in cooperation with universities and individual physicians. A mathematical model, a micro motion measuring device, a non invasive bladder pressure measuring device and a wireless electronic bladder sensor. Two of these devices are now on the market: the mathematical model and the non invasive bladder pressure measuring device that is marketed by a British firm.

Research and product developments continue. For two years now, Laborie is the only manufacturer of urodynamics equipment using wireless technology.

I depend on engineers who work in the company to develop, to perfect and to offer their ideas as well, not just mine. We also work with universities but we cannot do that in the US unfortunately because universities here are for profit and our budget does not allow us to pay for that. As a small group of people we are dedicated to making incontinence and everything associated with it as tolerable for the patients as possible.

Note: This C.V. is in fact a C.V. of the company that is made up of many individuals, some of great competence. Whatever has been accomplished by this company is the result of a common effort by the members of this company.

Monica Liebert, PhD

Monica Liebert, PhD, is currently the Director of Research at the American Urological Association (AUA) Foundation. The mission of the AUA Foundation Office of Research is to “improve the care and treatment of patients with urological diseases through enhanced urology research.” Dr. Liebert joined the AUA from the National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, where she served as Program Officer for the Urology Basic Sciences Program. She has previously held faculty positions at The University of Texas-M.D. Anderson Cancer Center in Houston , and the University of Michigan , and served from 1997-1999 as the Deputy Director for the Prostate Cancer Research Program at the Congressionally-Directed Medical Research Programs for the Department of Defense. She is a member of a number of advisory, program and review committees. Dr. Liebert has authored or contributed to more than 70 scientific articles and book chapters. Her research work on bladder diseases has been supported by peer-reviewed funding from the NIH and American Cancer Society. She is continuing her basic research as an Adjunct Professor in the Department of Urology at the University of Michigan .

Alvin Maslov, MSEE, MBA

Work Experience

Hollister Incorporated, a global medical device manufacturing/marketing company, specializing in ostomy, wound, continence, mother/baby care and patient identification/security products.

1982 -1984 Director of Marketing , USA

1984 – 1995 Director of International Marketing and Administrative Services

1995 - 2000 Group Product Manager, Asia, Latin America, Middle East and Africa Division

2001 – current Manager, Customer and Professional Relations, Global Marketing Organization

Baxter International, a multinational company specializing in a broad range of medical diagnostic, therapeutic and management products.

1976 - 1982 Director of Product Planning, Renal Therapy (Dialysis) and Cardiopulmonary (Heart-Lung) Systems

IBM Corporation

1970 – 1976 Process Control / Laboratory Automation Computer Systems Specialist


Masters Business Administration (MBA), University of Chicago

Master of Science Electrical Engineering (MSEE), University of Illinois

Bachelor of Science Electrical Engineering (BSEE), University of Illinois

Christopher K. Payne, MD, FACS

Christopher Payne grew up in West Virginia and attended undergraduate school at the University of Virginia where he received a BA degree in Chemistry with a minor in English. He attended Vanderbilt University for medical school after which he completed a urology residency at The Hospital of the University of Pennsylvania in Philadelphia , Pennsylvania . He subsequently completed a fellowship in Female Urology, Urodynamics, and Pelvic Reconstructive Surgery at UCLA in 1992-1993. He was recruited to Stanford University in August 1993 to initiate a new program in Female Urology and NeuroUrology.

Dr. Payne is nationally recognized as a leader on issues in female urology having served on NIH advisory panels on urinary incontinence and interstitial cystitis and a member of the panel which defined bladder research priorities for the 21st century at a meeting sponsored by the Office of Women’s Health Research. He is a current member of the medical advisory board for the Interstitial Cystitis Association. He has published numerous articles and book chapters on urinary incontinence and surgical reconstruction. He has been an invited faculty member at both international and national meetings and was invited to address the plenary session of the American Urological Association meeting in 1998 and 2005. His expertise in clinical research has been recognized through two NIH principal investigator grants focusing on treatment of interstitial cystitis and appointment as Chair of the Research Methodology subcommittee for the World Health Organization’s International Consultation on Incontinence.

Dr. Payne’s practice is concentrated in three areas—surgical treatment of urinary incontinence and pelvic prolapse, clinical trials in interstitial cystitis and urinary incontinence, and urodynamic evaluation of complex bladder dysfunction.

Clinical Interests

Male and Female Urinary Incontinence

Pelvic Prolapse

Interstitial Cystitis

Urinary Obstruction and Fistulas

Minimally invasive treatment of male voiding dysfunction/BPH

Current Research Projects

Interstitial Cystitis NIH clinical trials group

Different methods of anesthetizing the bladder in chronic pain

Use of iontophoresis to perform office bladder distention

Novel method for sacral nerve stimulation

Karl B. Thor, PhD

Karl B. Thor, PhD, formed Urogenix, Inc., as a subsidiary of Astellas Pharmaceuticals, Inc., in March of 2007 and holds the position of vice-president of research. In addition, Dr. Thor holds Adjunct Research Associate Professor positions in the Department of Surgery/Division of Urology and the Department of Obstetrics and Gynecology at Duke University Medical Center in Durham , North Carolina . He is Co-Director of the Laboratory of Neurourology at the Veterans Affairs Medical Center , Surgical Research Services, also in Durham . The Laboratory of Neurourology receives grant support from the NIH, Veterans Administration, and Christopher Reeves Foundation for studies of neural control of the lower urinary tract under pathological conditions including spinal cord injury.

Dr. Thor received his PhD in Pharmacology from the University of Pittsburgh School of Medicine where he trained under William (Chet) de Groat, Ph.D. and was supported by a PhARMA predoctoral fellowship. He held a National Research Service Award postdoctoral fellowship from the NIH at Uniformed Services University of the Health Sciences in Bethesda , Maryland , and was a S eni or Staff Fellow in the Laboratory of Neurophysiology at the NIH. He joined Eli Lilly in the Neuroscience Division in 1990, where he discovered duloxetine (Yentreve) as a treatment for stress urinary incontinence. In 1998, he formed PPD GenuPro as a subsidiary of PPD Inc., where he discovered the clinical potential of dapoxetine as a therapy for premature ejaculation. These 2 drugs are the first agents to be submitted to regulatory agencies for their respective indications. In 2002, he founded Dynogen Pharmaceuticals Inc., a neuroscience-based drug discovery and development company targeting g eni tourinary and gastrointestinal diseases, where 2 clinical program for overactive bladder and 2 clinical programs for irritable bowel syndrome were initiated.

Dr. Thor has published numerous articles and book chapters on CNS control of lower urinary tract function and holds several patents for methods of treating urinary bladder and sexual dysfunction. He is a member of the Urodynamics Society, the International Continence Society, and the Society for Neuroscience. He served as a member of the FDA-PhARMA Industry Guidelines for Urinary Incontinence Trials in 1998. He has served as a peer reviewer for the NIH on the Urology Special Emphasis Study Section, the National Institutes of Neurological Disorders and Stroke Neurology B Study Section, and the Small Business Initiative Review Study Section. He has served on the World Health Organization’s International Consultation on Incontinence since its inception.